Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4233)
All Articles published online
|
Publishing Process of This Article
|
Nov 24, 2021 (publication date) through Nov 9, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Isaksson J, Green H, Papantoniou D, Pettersson L, Anden M, Rosell J, Åvall-Lundqvist E, Elander NO. Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer. World J Clin Oncol 2021; 12(11): 1009-1022 [PMID: 34909396 DOI: 10.5306/wjco.v12.i11.1009] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v12/i11/1009.htm |
| Number | Citing Articles |
| 1 |
Shintaro Narita, Takahiro Kimura, Shingo Hatakeyama, Kenichi Hata, Takafumi Yanagisawa, Shinya Maita, Shuji Chiba, Hiromi Sato, Soki Kashima, Atsushi Koizumi, Ryohei Yamamoto, Koichiro Takayama, Katsumi Okane, Toshiya Ishida, Yohei Horikawa, Teruaki Kumazawa, Jiro Shimoda, Takehiro Suzuki, Chikara Ohyama, Shin Egawa, Tomonori Habuchi. Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel. International Journal of Clinical Oncology 2022; 27(9): 1477 doi: 10.1007/s10147-022-02203-y
|
| 2 |
Benjamin Lowentritt, Dominic Pilon, Dexter Waters, Carmine Rossi, Erik Muser, Siyana Kurteva, Aditi Shah, Ibrahim Khilfeh, Shawn Du, Lorie Ellis, Patrick Lefebvre, Gordon Brown. Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study. Urologic Oncology: Seminars and Original Investigations 2023; 41(5): 252.e19 doi: 10.1016/j.urolonc.2023.03.013
|
| 3 |
Anne Holck Storås, Kaitlyn Tsuruda, Sophie Dorothea Fosså, Bettina Kulle Andreassen. Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study. Acta Oncologica 2023; 62(12): 1716 doi: 10.1080/0284186X.2023.2257876
|
| 4 |
Benjamin Lowentritt, Dominic Pilon, Ibrahim Khilfeh, Carmine Rossi, Erik Muser, Frederic Kinkead, Dexter Waters, Lorie Ellis, Patrick Lefebvre, Gordon Brown. Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide. Urologic Oncology: Seminars and Original Investigations 2023; 41(5): 253.e1 doi: 10.1016/j.urolonc.2023.03.003
|